DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.

Event context and recent share performance DexCom (DXCM) shares have been under pressure recently, with the stock down about 3% over the past month and 8.6% over the past 3 months, while the business ...

Over the last six months, DexCom’s shares have sunk to $62.07, producing a disappointing 6.4% loss - a stark contrast to the ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

DexCom's Q3 performance shows impressive organic growth rates and increased revenue guidance for 2023. The company's strategic focus on international markets and expanding customer bases indicates ...

Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...